Parkinson's Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
, /PRNewswire/ -- Parkinson's disease (PD) is a neurodegenerative disorder that affects predominately dopamine-producing ("dopaminergic") neurons in a specific area of the brain called substantia nigra. Symptoms generally develop slowly over years. The pr...
PR Newswire - PRF · 12h ago
Is a Beat in Store for Zoetis (ZTS) This Earnings Season? · 2d ago
William Blair Reiterates a Buy Rating on Axsome Therapeutics (AXSM)
William Blair analyst Myles Minter reiterated a Buy rating on Axsome Therapeutics (AXSM) on April 26. The company's shares closed last Friday at $60.50.
SmarterAnalyst · 5d ago
Advanced Liver Cancer Drug Pipeline Prospers with an Inrush of Pharma Companies and Emerging Novel Therapies
Los Angeles, USA, Apr 29, 2021 (GLOBE NEWSWIRE via COMTEX) -- Los Angeles, USA, April 29, 2021 (GLOBE NEWSWIRE) -- Advanced Liver Cancer Drug Pipeline...
GlobeNewswire · 6d ago
Leerink Partners Thinks Axsome Therapeutics’ Stock is Going to Recover
Leerink Partners analyst Marc Goodman maintained a Buy rating on Axsome Therapeutics (AXSM) on April 26. The company's shares closed last Wednesday at
SmarterAnalyst · 6d ago
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards? · 04/28 13:15
Axsome Therapeutics to Report First Quarter 2021 Financial Results on May 10, 2021
Axsome to host conference call and webcast on Monday, May 10, 2021 at 8:00 AM Eastern Time NEW YORK, April 27, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of c...
GlobeNewswire · 04/27 11:00
DJ Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/27 10:41
58 Biggest Movers From Yesterday
Benzinga · 04/27 09:03
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc.
Benzinga · 04/26 18:18
38 Stocks Moving In Monday's Mid-Day Session
Benzinga · 04/26 16:09
Reviva Pharmaceuticals, Ocugen leads healthcare gainers; MiMedx, Shineco among major losers
Gainers: Reviva Pharmaceuticals RVPH +41%, Ocugen OCGN +22%, Axsome Therapeutics AXSM +12%, AcelRx Pharmaceuticals (ACRX) +9%, Voyager Therapeutics VYGR +8%.Losers: MiMedx (MDXG) -9%, Shineco (TYHT) -8%, Brooklyn ImmunoTherapeutics (BTX) -4%.
Seekingalpha · 04/26 15:02
DJ Axsome Shares Rise on FDA Priority Review of AXS-05 >AXSM
Dow Jones · 04/26 14:59
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards? · 04/26 13:42
Thinking About Buying Stock In Immunome, Axsome Or Etsy?
Immunome Inc (NASDAQ: IMNM) shares are trading higher by 9.25% by $32.28 after the company reported that its SARS-CoV-2 antibody cocktail neutralizes the UK, South Africa, Brazil and California variants in its preclinical testing.
Benzinga · 04/26 13:32
RIOT, MARA, OCGN and MVIS among notable premarket gainers
Scienjoy Holding Corporation (SJ) +29% on launching Non-Fungible Tokens on its platforms.MICT (MICT) +17%.Ocugen (OCGN) +15%.BrainsWay (BWAY) +14% on FDA clearance for Deep TMS protocol.China Recycling Energy (CREG) +13%.Axsome Therapeutics (AXSM) +12% on
Seekingalpha · 04/26 12:21
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 04/26 12:10
Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive Disorder
Benzinga · 04/26 11:54
Axsome’s marketing application for AXS-05 accepted by FDA under priority review
Axsome Therapeutics (AXSM) has risen ~14.5% in the pre-market after the company announced the FDA acceptance of its New Drug Application (“NDA”) for AXS-05 for the treatment of the major depressive disorder (“MDD”).With the
Seekingalpha · 04/26 10:53
BRIEF-Axsome Therapeutics Announces FDA Acceptance And Priority Review Of New Drug Application For Axs-05 For Treatment Of Major Depressive Disorder · 04/26 10:41
Webull provides a variety of real-time AXSM stock news. You can receive the latest news about Axsome through multiple platforms. This information may help you make smarter investment decisions.
About AXSM
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).